Dr Sean Gill and Dr Chetan Mukhtyar (Norfolk and Norwich University Hospital, UK) discuss the efficacy of tocilizumab for GCA, based on a 12-month extension of Stone et al.’s landmark clinical trial. Dr Mukhtyar provides an overview of the trial, including key findings, limitations, and implications for clinical practice.

Read the paper: https://doi.org/10.1093/rheumatology/keab418

Keywords: Giant cell arteritis, GCA, vasculitis, large vessel, tocilizumab, rheumatology, treatment, biologic, biological therapy, IL-6

Thanks for listening to Talking Rheumatology Research! Join the conversation on X using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram and LinkedIn.

Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.